Two recently published studies led by Mt. Sinai researchers may
offer new hope from "old medicine" for cancers including a quarter of
breast cancers. Their report: Repurposing a Drug to Prevent and Treat
Cancers, refers to their work with bisphosphonates--the osteoporosis drugs.
So it was not a surprise to learn that lead study author and professor Mone Zaidi, MD, PhD, FRCP, also heads the Mt. Sinai Bone Program. The surprise was reading the cautious statement that
So it was not a surprise to learn that lead study author and professor Mone Zaidi, MD, PhD, FRCP, also heads the Mt. Sinai Bone Program. The surprise was reading the cautious statement that
"Bisphosphonates have been previously associated with slower
tumor growth
in some patients..."
***
I dug around some. Found tumors in a bone treatment article on
OncoLink, a site of The
Abramson Cancer Center of the University of Pennsylvania Last
Modified: December 18, 2014.
They
were cautious, too. But down in the bisphosphonates section I found:
"Bisphosphonates may have some level of anti-tumor activity in breast cancer.
A recent Phase III clinical trial revealed that the addition of Zometa to endocrine therapy, improves
disease-free survival...in pre-menopausal patients with estrogen-receptor
positive early breast cancer."
Since my DCIS was hormone receptive, that sounded like good news for me.
However their mention of other clinical trials in progress at the time,
does not include HER2.
***
So I was back to the Mt. Sinai research:
You probably know that HERs are human epidermal growth factor receptors. The Mt. Sinai article outlines their first study, that revealed how bisphosphonates work.
You probably know that HERs are human epidermal growth factor receptors. The Mt. Sinai article outlines their first study, that revealed how bisphosphonates work.
With that study's discoveries, and with the knowledge that
twenty five per cent of breast cancers "proceed from genetic changes that result in excessive amounts of HER2" they started the second study.
The researchers went into the labs, which revealed:
The researchers went into the labs, which revealed:
Giving mice bisphosphonates early on
prevented HER-driven tumors from forming, and combining bisphosphonates with
the cancer drug Tarceva® not only stopped tumor growth but reversed it.
So now we wait. Dr. Zaidi reminds us we may get this Bc treatment
"... if we can confirm in clinical trials that
this drug class also reduces
cancer growth in people.”
We can’t know how long it will be before their trials are up and running. Some women will undoubtedly comb the web and learn more before I do. Please share what you learn with us.
I wish you health.
PS If you are on Twitter, check out the great"cartoon style" dwgs on immune checkpoints & how they work @JAMAOnc
No comments:
Post a Comment